adalimumab

Ligand id: 4860

Name: adalimumab

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: adalimumab

References
1. Bandyopadhyay S, Mahajan M, Mehta T, Singh AK, Parikh A, Gupta AK, Kalita P, Patel M, Mendiratta SK. (2015)
Physicochemical and functional characterization of a biosimilar adalimumab ZRC-3197.
Biosimilars5: 1-18.
2. Jaffe GJ, Dick AD, Brézin AP, Nguyen QD, Thorne JE, Kestelyn P, Barisani-Asenbauer T, Franco P, Heiligenhaus A, Scales D et al.. (2016)
Adalimumab in Patients with Active Noninfectious Uveitis.
N. Engl. J. Med.375 (10): 932-43. [PMID:27602665]
3. Jani RH, Gupta R, Bhatia G, Rathi G, Ashok Kumar P, Sharma R, Kumar U, Gauri LA, Jadhav P, Bartakke G et al.. (2015)
A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis.
Int J Rheum Dis,  [Epub ahead of print]. [PMID:26176644]
4. Kawalec P, Mikrut A, Wiśniewska N, Pilc A. (2013)
Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis.
Arch Med Sci9 (5): 765-779. [PMID:24273556]
5. Kempeni J. (1999)
Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7.
Ann. Rheum. Dis.58 Suppl 1: I70-2. [PMID:10577977]
6. Puri A, Niewiarowski A, Arai Y, Nomura H, Baird M, Dalrymple I, Warrington S, Boyce M. (2017)
Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab/Humira, in healthy subjects.
Br J Clin Pharmacol,  [Epub ahead of print]. [PMID:28133772]
7. Rau R. (2002)
Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials.
Ann. Rheum. Dis.61 Suppl 2: ii70-3. [PMID:12379628]
8. Salfeld JG, Allen DJ, Hoogenboom HRJM, Kaymakcalan Z, Labkovsky B, Mankovich JA, McGuinness BT, Roberts AJ, Sakorafas P, Schoenhaut D. (2001)
Human antibodies that bind human TNFα.
Patent number: US6258562. Assignee: Basf Aktiengesellschaft. Priority date: 09/02/1996. Publication date: 10/07/2001.
9. Wollheim FA. (2002)
TNF inhibition as therapy for rheumatoid arthritis.
Expert Opin Investig Drugs11 (7): 947-53. [PMID:12084005]